Biocon Limited, a global biopharmaceutical company, is focused on developing and supplying affordable medicines for patients worldwide through its biosimilars and generic medicines businesses. Listed on the BSE under code 532523 and on the NSE under the symbol BIOCON, the company addresses healthcare needs across chronic and non-communicable diseases. Its portfolio covers diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology and bone health.
Biocon has commercialised 12 biosimilar products and more than 30 generic formulations globally. Its research and development pipeline includes more than 20 biosimilar assets, along with GLP-1 peptides and other complex generic medicines. The company’s activities span research, product development, manufacturing and commercial operations, supporting the supply of medicines across multiple markets.
The company operates in more than 120 countries, supported by seven manufacturing sites, three research and development facilities and 18 offices worldwide. Its workforce comprises more than 9,500 employees. Biocon’s biosimilars business has contributed to the company’s position in the global market for biologic medicines. Biosimilars are highly similar versions of approved biological medicines and can provide additional treatment options as patents on reference products expire. The development and manufacture of these products require specialised scientific expertise, quality systems and production capabilities.
Alongside biosimilars, Biocon’s generics business supplies medicines for a range of therapeutic areas. The company is also developing complex generic formulations and GLP-1 peptides, reflecting its focus on products that require advanced development and manufacturing capabilities.
Biocon follows an integrated operating model that connects research and development with manufacturing and commercialisation. This approach is intended to support product development, quality management and reliable supply across the markets it serves. The company’s focus areas include therapies for conditions that affect large patient populations, including diabetes, cancer and cardiovascular disease. Its portfolio also addresses immunological disorders, eye conditions and bone health. Through its presence across multiple geographies, Biocon aims to make treatments available to patients in different healthcare systems.
Biocon has also been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year. The recognition reflects the company’s performance in sustainability-related assessments and its efforts to incorporate responsible business practices into its operations.
The company continues to develop its research pipeline while expanding its global commercial reach. Its work across biosimilars, generics and complex medicines forms part of its broader focus on improving access to treatment through pharmaceutical development and manufacturing.
Biocon Limited is a Bengaluru-headquartered biopharmaceutical company focused on affordable medicines. Its portfolio includes biosimilars and generic formulations across several major therapeutic areas. The company operates internationally through an integrated model covering research and development, manufacturing and commercialisation, with facilities and offices supporting its activities in more than 120 countries.
